Author: CannabisNewsWire (CNW)

About CannabisNewsWire CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge. To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CannabisNewsWire.com Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

420 with CNW — Marijuana Use Could Trigger Epigenetic Changes, Study Finds

A recent study involving more than 1,000 adults suggests that marijuana use may influence changes in the body’s epigenome, which acts like a series of switches turning genes on or off to regulate bodily functions.

According to Northwestern University epidemiologist Lifang Hou, the study discovered connections between long-term cannabis use and various epigenetic markers over time. While several U.S. states and countries have legalized its use, the full impact on health remains unclear.

According to Hou and her team of researchers from the U.S., about half of all Americans have at least one cannabis experience. Its full health impact is yet unknown, despite numerous U.S. states and other nations having approved its usage.

The research examined individuals who had taken part in a long-term study tracking their cannabis use for two decades. Participants, aged 18 to 30 at the start, provided blood samples twice—once at the 15-year mark and again at 20 years.

Scientists analyzed these samples to detect changes in DNA methylation, a key epigenetic process. DNA methylation involves adding or removing methyl groups from DNA, which alters gene activity without modifying the genetic sequence. These modifications can be triggered by lifestyle and environmental factors and might even be inherited by future generations. Blood biomarkers serve as indicators of both long-term and recent exposures.

Hou explained that previous research had already linked cannabis use to DNA methylation patterns associated with aging. The new study aimed to explore whether specific epigenetic changes related to cannabis use could influence health outcomes.

The researchers compared cumulative and recent marijuana use with DNA methylation indicators in participants’ blood. At the 15-year mark, they identified 22 markers tied to recent cannabis use and 31 linked to long-term use. Five years later, at the 20-year point, they found 132 markers associated with recent use and 16 related to long-term use.

One particular marker repeatedly appeared in the study, which had also been linked to tobacco use. Hou noted that this could suggest a common epigenetic response to both substances. Other marijuana-related epigenetic changes had been previously associated with processes like cell growth, hormone regulation, infections, and neurological conditions such as bipolar disorder and schizophrenia.

However, the study does not confirm that marijuana directly causes these epigenetic changes or leads to specific health problems. Drew Nannini, also a Northwestern University epidemiologist, stressed that more studies are needed to verify the findings across different populations.

There is a lot more that needs to be studied about marijuana, which is why the entire industry, including firms like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF) have for long wanted to see reforms in marijuana policy made at the federal level so that it is easier to conduct studies on this plant and its products. The findings can help to address some of the concerns arising or dispel some misconceptions about this plant.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of an article each business day at 4:20 p.m. Eastern – a tribute to the time synonymous with cannabis culture. The concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — This New THC-Free Marijuana Compound Could Replace Opioids

A recent study from the University of Arizona Health Sciences suggests that terpenes found in the marijuana plant may offer a new way to manage post-surgical and fibromyalgia pain. The study expands on prior research conducted by Comprehensive Center for Pain and Addiction member Dr. John Streicher, who previously explored the pain-relieving properties of terpenes in cases of inflammation and nerve pain caused by chemotherapy.

According to Streicher, terpenes do not seem effective for immediate pain relief, such as injuries from burns or stubbing a toe. However, they show promise for pathological or long-term pain conditions. This study marks the first preclinical examination of terpenes in treating post-surgical and fibromyalgia pain, expanding potential non-opioid treatment options.

The research team focused on four terpenes commonly found in marijuana: alpha-humulene, geraniol, beta-caryophyllene, and linalool. In mouse models, all four provided significant pain reduction, with geraniol showing the most substantial effect.

Fibromyalgia, a chronic condition affecting muscles and soft tissues, impacts up to 5% of the global population, according to a 2023 study. In the U.S., approximately 4 million adults suffer from the condition, with women being more affected than men. Current treatments for fibromyalgia are limited, making new approaches like terpene-based therapy particularly important.

Post-surgical pain exists between chronic and acute pain, typically resolving in a short time but sometimes leading to complications due to heightened pain sensitivity and inflammation. While opioids are commonly prescribed for such pain, they can cause side effects like constipation, which may increase the risk of adhesions.

Streicher and his team are investigating alternative solutions, and their findings suggest terpenes could serve as a new therapeutic option.

Each year, around 310 million major surgical procedures take place worldwide. Given the widespread need for post-surgical pain management, identifying non-opioid treatments is a critical area of research.

The Comprehensive Center for Pain and Addiction’s director, Dr. Todd Vanderah, stressed the value of basic research in the development of novel therapies. He pointed out that many chemical compounds with unrealized medical potential are produced by plants, including marijuana. To illustrate how nature still produces surprising medical advances, he likened this to semaglutide (Ozempic), a drug created from a chemical found in the Gila monster.

The study also confirmed that terpenes interact with the adenosine A2a receptor, the same target as caffeine. This finding suggests that terpenes may have sedative effects, opening avenues for further research into their broader therapeutic potential.

Marijuana firms, such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQB: CURLF), are likely to take an interest in such studies since they could open opportunities for them to develop products geared at addressing the medical needs of specific symptoms afflicting their clients.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Divisive Colorado Cannabis Potency Bill Withdrawn at Committee Stage

A contentious bipartisan measure aimed at addressing the high potency of cannabis in Colorado was withdrawn by its sponsors during a committee hearing. The measure faced immediate backlash, particularly over proposed regulations on specific edibles and age restrictions.

Before the first reading, Senator Judy Amabile indicated she planned to revise the measure significantly. However, when the hearing took place, she instead requested the panel to reject it. The bill had already stirred debate, prompting its sponsors to promise changes before the official discussion even began.

Currently, Colorado law limits THC levels in edibles to 10 milligrams per serving. The bill sought to extend that restriction to vaping and smoking cannabis products. Additionally, it proposed a new labeling scheme to help provide users with a deeper understanding of potency levels.

One of the most controversial aspects of the measure—initially included but later abandoned—was a cap on the quantity and potency of marijuana that individuals under the age of 25 could purchase. That provision drew the most resistance from the public, particularly in online discussions.

Lawmakers justified the age-related restriction by citing concerns about brain development, referencing CDC findings that suggest cannabis may have long-term effects on memory, attention, and learning, though further research is needed.

Since cannabis was legalized in Colorado, THC levels in marijuana flower have significantly increased. According to the NIH, between 1990 and 2015, the average THC potency in marijuana flower rose by 212%. The industry has also introduced highly concentrated products like edibles, wax, and vape oils, contributing to growing concerns over potency.

Another provision in the measure sought to prevent holders of natural medicine licenses—such as those handling psilocybin—from manufacturing, transferring, or distributing infused candy items, including chocolates and gummies.

Supporters of the measure argued that such products are more appealing to children. However, psilocybin therapy advocates countered that the restriction was unnecessary since retail sales of the substance are not allowed in Colorado, reducing the risk of unauthorized access.

Senators Amabile and Byron Pelton introduced the measure after schools and parents raised concerns about the impact of highly potent cannabis on young people. Amabile also cited personal experience, explaining that her child developed schizoaffective disorder and psychosis after early and consistent cannabis use.

Jon Spadafora, CEO and founder of Flower Union Brands, a marijuana edibles company, argued that measures like these contribute to negative stereotypes about cannabis. He also warned that limiting purchases for younger consumers could hurt the industry by cutting off a significant portion of its users.

Acknowledging the backlash, Amabile confirmed that the age restriction would be removed. The measure would still require producers to adopt a new color-coded labeling system to indicate potency, with dispensaries posting signs explaining the meaning of the colors.

The overall marijuana industry, including enterprises like Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), could be glad that efforts to add another layer of complexity to the legal marijuana industry in Colorado has fizzled out in the dust.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Idaho Senate Passes Bill Giving Legislature Power Over Cannabis Legalization

The Idaho State Senate has approved a proposed constitutional amendment that would give the legislature sole authority to legalize cannabis and other drugs. The measure, known as House Joint Memorial 4, will be put to a vote in the November 2026 elections.

If passed by a majority of voters, the amendment would eliminate the ability of Idaho residents to legalize cannabis through citizen-led ballot initiatives. The language of the proposed amendment states that only the state legislature would have the power to permit the use, possession, cultivation, sale, and production of cannabis and other psychoactive substances.

Supporters argue that the measure reinforces Idaho’s strict stance on cannabis, setting it apart from neighboring states that have embraced recreational or medical marijuana. Senator Scott Grow, co-sponsor of the amendment, believes it is necessary to prevent the legislature from being pressured by repeated ballot initiatives.

He emphasized that lawmakers have a duty to uphold the state’s values and referenced a section of the Idaho Constitution that prioritizes morality and temperance in governance.

Critics, however, see the measure as a way to strip power from voters. Opponents argue that Idaho’s initiative process is a fundamental part of democracy, allowing citizens to directly propose and enact laws. They believe the amendment reflects a lack of trust in voters and undermines direct democracy.

Sen. James Ruchti, D-Pocatello, voiced concerns that the amendment undermines the principle that political power ultimately resides with the people, stating that voters should retain their right to decide on important legislative matters.

For over a decade, advocates have struggled to gather enough signatures to place a cannabis decriminalization measure on the ballot. Currently, efforts are underway to qualify a ballot initiative for the 2026 election, though it remains uncertain whether it will meet the necessary criteria.

A two-thirds majority vote is required in both legislative chambers to advance a constitutional amendment in Idaho. The Idaho Senate passed the proposal with a 29-6 vote, following the House’s 58-10 approval on March 5. When the amendment appears on the ballot in 2026, a simple voter majority will determine whether it becomes law.

The current proposed amendment follows another anti-cannabis measure enacted earlier in 2025. On February 24, Governor Brad Little signed into law a measure mandating a minimum fine of $300 for individuals convicted of possessing cannabis, further reinforcing the state’s firm stance against legalization.

Companies like Canopy Growth Corp. (NASDAQ: CGC) (TSX: WEED) could be reading the news coming out of Idaho and shaking their heads at how far some lawmakers can go to entrench their own preferences at the expense of those of the people who voted them into office.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Coalition Government Talks in Germany Could Be Complicated by Marijuana Policy

Germany’s coalition negotiations could become tense as the Christian Democrats (CDU) and Social Democrats (SPD) clash over the country’s marijuana law. The SPD, which championed the legislation last year, considers it a key achievement, while the CDU has always opposed legalization.

Following initial post-election discussions, CDU leader Friedrich Merz expressed optimism about forming a coalition government with SPD, describing the talks as productive. However, this cooperative atmosphere may not last.

The SPD-led coalition, which included the Greens and Free Democrats (FDP), pushed for the legislation in April last year, bringing Germany in line with the Netherlands, Portugal, Spain, Malta, and Belgium in decriminalizing marijuana.

Merz previously stated his party’s opposition to the law, telling Tagesschau before the election that the CDU intended to “fix” the law. Their manifesto went further, labeling legalization a failure and pledging to remove it.

The SPD, on the other hand, is still committed to cannabis reform and even called for further changes aligning with European standards.

Ahead of coalition discussions, CDU health policy representative Tino Sorge criticized the law as a “dangerous mistake,” arguing that it should be repealed. However, he acknowledged that coalition talks would ultimately determine the outcome. Given the differing positions and economic factors at play, a compromise appears likely.

The industry remains hopeful that a complete rollback is unlikely. Bloomwell Group CEO Niklas Kouparanis expressed confidence that major changes wouldn’t disrupt Germany’s medical marijuana market. He argued that reclassifying marijuana as a narcotic would be a complex and time-consuming process. Instead, he expects adjustments such as stricter regulations on nonprofit marijuana clubs and home cultivation limits.

From an industry perspective, the SPD’s legalization effort has positioned Germany as a key player in the medical marijuana sector. Any reversal could break an election promise and expose the government to legal challenges.

By November last year, nearly 400 marijuana social clubs had applied for licenses, though only a fraction had received approval. Kouparanis warned that revoking the law could lead to legal claims from already licensed clubs seeking compensation.

Beyond legal concerns, the economic impact is substantial. Sales of cannabis-based medicines covered by health insurance have doubled in three years, with further growth expected. Imports of medical marijuana quadrupled in 2024, with shipments rising to 31.7 tons over the year.

The CDU’s economic priorities might influence future policy. A CDU-led government could take a state-controlled but economically sensible approach to healthcare. Given the SPD’s weaker position in coalition talks, their ability to protect cannabis legislation remains uncertain.

Major North American marijuana companies like Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) are likely to keep tabs on the unfolding situation in Germany in order to assess whether potential market opportunities emerge or the new government scuttles the progress made in reforming the country’s drug laws.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — States are Scrambling to Get Reliable Tools to Detect Marijuana Impairment in Drivers

Minnesota is among several states testing a new device that detects THC in saliva, similar to a Keurig machine. The pilot program, which ended earlier this year, is now under review by the state patrol, which plans to present its findings to state legislators.

With cannabis now legal in most states, its use has grown and more people are consuming it before driving. States have laws against driving under the influence of substances, but regulating cannabis impairment remains a challenge. Unlike alcohol, where a breathalyzer provides a clear measure of intoxication, THC affects individuals differently based on tolerance, making it hard to set a standard.

Studies suggest that THC impairs driving by reducing reaction time, slowing speed, and causing swerving. However, determining the actual risk remains complex. In Colorado, fatal accidents involving drivers with THC in their system increased post-legalization, yet it’s difficult to confirm if they were impaired at the time of the crash.

Alcohol breath tests work well because breath alcohol levels closely match blood and brain alcohol levels. THC, on the other hand, can stay in the body long after its effects wear off, making it unreliable as an immediate impairment indicator. This has led private companies, state agencies, and researchers to look for a more accurate roadside test.

Other states, including Wisconsin, Alabama, Indiana, Colorado and Michigan have used or considered saliva-based THC tests. Missouri police have experimented with goggles that analyze pupil movement and size. Meanwhile, Colorado researchers are exploring THC breathalyzers. In Illinois and Vermont, teams have created apps designed to assess cognitive function in real time.

Colonel Matthew Packard, head of the Colorado State Patrol, believes training officers to recognize impairment remains crucial, even without a definitive test. His department has conducted “green labs,” where volunteers use cannabis in front of law enforcement officers to help them identify impairment signs more accurately.

However, some argue that relying solely on police judgment is too subjective. Jordan Wellington, a marijuana policy expert at Strategies 64, points out that officers, like anyone else, are not infallible. While developing a reliable impairment test is an important goal, he believes public education on cannabis and the impact of driving under the influence is even more critical to improving road and public safety.

“If people avoided driving while impaired, we wouldn’t need to focus as much on detecting impairment,” Wellington says. “The real issue is people making poor decisions before they get behind the wheel.”

Major marijuana entities like Verano Holdings Corp. (OTCQX: VRNOF) hope that efforts to get reliable tests for marijuana intoxication yield results soon so that any claims that cannabis leads to increases in traffic accidents can be verified or debunked using concrete data from the field.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — The Marijuana Industry is Pivoting to Address Women’s Wellness Needs

Women are playing a major role in shaping the marijuana sector, influencing market trends and driving innovation. Brands are adjusting to meet the demands of women who are increasingly using marijuana for wellness advantages, including stress relief, pain treatment, and improved sleep, by providing products that fit with a health-conscious lifestyle.

The industry is seeing a rise in marijuana-infused wellness products, from edibles designed for relaxation to self-care items such as beauty creams and balms. Companies recognizing this shift can tap into a growing consumer base and remain competitive.

According to David Kooi, CEO of Jointly, a Los Angeles-based marijuana discovery app, women are driving the movement toward intentional marijuana use and giving wellness-related objectives top priority.

According to the app, 55% of its consumers are women, and they are more likely than men to use cannabis with a partner. Additionally, women report a higher success rate in using marijuana for pain relief and recovery.

Recent studies highlight the increasing prevalence of cannabis consumption among women. A 2023 study revealed that women between 19 and 30 surpassed men in cannabis use for the first time since 1975.

Creating products that integrate seamlessly into women’s daily routines is crucial, according to Grasslands’ COO Chloe Steerman. She noted that simply branding a product in feminine colors is no longer effective. “Women are discerning consumers who know exactly what they want,” she said. The challenge lies in getting industry executives to take these insights seriously.

Narmin Jarrous, chief development officer at Michigan-based Exclusive Brands, successfully launched Neno’s Naturals to help manage her endometriosis symptoms. Unlike many women in the industry, she had decision-making power and was able to develop a product that addressed a real medical need.

Jarrous urges companies to consider women’s health concerns, such as menstrual pain and endometriosis, when formulating new products. “Women not only make up a significant portion of marijuana consumers, but they also influence household purchasing decisions,” she pointed out.

Veda Warrior CEO Smrita Choubey incorporates Ayurvedic principles into her marijuana-infused butter and cooking oils, with 65% of her customer base being women. While the company maintains gender-neutral branding, it is developing a new line of balms and gummies tailored to women’s needs, including cramp relief.

Other companies are also recognizing the growing influence of female consumers. Connected Cannabis Co. is partnering with Kush Queen for International Women’s Month, launching a product bundle designed to enhance intimacy and wellness.

As women continue to drive demand in the marijuana market, businesses that listen to their needs and create thoughtful, wellness-oriented products will be well-positioned for success. It won’t be surprising when leading brands like TerrAscend Corp. (TSX: TSND) (OTCQX: TSNDF) gradually increase the number of products they offer to meet the specific wellness needs of women in the markets they serve.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Government-Funded Research Shows Including CBD While Making Dentures Staves Off Oral Infections

A recently published study suggests that integrating CBD into denture materials may help prevent oral infections. The research, which appeared last month in the journal Molecules and backed by government funding, indicates that incorporating CBD into dentures could provide an antibiotic-free method to reduce plaque buildup and improve oral hygiene.

To explore this possibility, scientists infused CBD into polymethyl methacrylate (PMMA), a plastic commonly used in dentures due to its durability and aesthetic appeal. They then evaluated its antimicrobial effects against three bacteria: Streptococcus agalactiae, Escherichia coli, and Staphylococcus aureus.

Findings revealed that CBD-coated dentures were highly effective in killing Gram-positive bacteria. While the coating did not eliminate free-floating Gram-negative bacteria, it successfully eradicated bacterial biofilms.

The study reported a remarkable 99% decrease in biofilm growth for Gram-negative and Gram-positive bacteria on CBD-treated PMMA compared to the standard material. Researchers noted that CBD caused bacterial cell walls to break down and be destroyed.

In certain instances, the contrast between normal and CBD-infused PMMA was striking. For instance, S. agalactiae growth was 10,000 times higher on regular PMMA than on the CBD-coated version. The research also documented a 99% drop in E. coli and S. aureus biofilms and an even greater 99.99% decrease in S. agalactiae biofilms.

One aspect requiring further examination is how to develop coatings that allow for a controlled and prolonged release of CBD to maximize its ability to combat bacteria over time. The researchers observed that CBD released rapidly within the first 12 hours before stabilizing and dispersing gradually in a controlled environment.

Another area for future investigation is why CBD coatings effectively eradicated biofilms but did not affect free-floating planktonic bacteria of the same species. The researchers suggest further research into the genetic mechanisms behind biofilm formation and maintenance, as well as the role of CBD in disrupting bacterial adhesion to surfaces.

These findings align with separate research that explored CBD’s antibacterial effects in other contexts.

One study found that CBD could help treat bacterial vaginosis by weakening Gardnerella vaginalis biofilms, which can disrupt the microbial balance in the vagina. Another study, published in Pharmaceuticals, suggested that CBD might have wound-healing and anti-aging properties, making it a valuable addition to skincare products.

As research into CBD’s medical applications continues, these studies highlight its potential as a natural antibacterial agent that could revolutionize dental and healthcare treatments.

These studies funded by the federal government are helping to confirm what is behind the popularity of marijuana brands and the mushrooming of ancillary enterprises like Innovative Industrial Properties Inc. (NYSE: IIPR) that have been established to address the niche needs of companies dealing directly in marijuana products.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Nebraska Former Governor, AG Ask Lawmakers to Disregard Ballot Decision Legalizing Medical Cannabis

Nebraska’s Attorney General Mike Hilgers and former Governor Pete Ricketts are asking the state legislature to reject two citizen-led initiatives concerning medical marijuana production, use, and possession. The measures were approved by about 70% of voters in the recent election.

In an opinion piece, Hilgers and Ricketts, now a U.S. Senator, urged lawmakers to disregard the voters’ decision stating that the legislature is not obligated to act on the matter. They expressed concerns over marijuana use, claiming it is harmful, prone to abuse, and unsafe even when used for medical purposes.

Ricketts, a long-time cannabis reform opponent, has previously made extreme claims, including saying that legalizing cannabis could put young people’s lives at risk. The Attorney General’s office warned that if regulators tried to license medical marijuana providers, the state would take legal action, alleging violations of federal law. Legalization opponents have sued to overturn the November election results.

Lawmakers recently heard arguments regarding a proposed law, Legislative Bill 483, which seeks to prevent patients from accessing cannabis in its natural form. Paul Armentano, Deputy Director of NORML, spoke against the measure, emphasizing that voters had clearly expressed their desire for regulated medical marijuana access.

He described the measure as both undemocratic and harmful to patients, explaining that restricting access to only pill or oral forms of cannabis could delay symptom relief for those experiencing nausea, pain, or muscle spasms.

Over 300 people provided testimony opposing LB 483.

Lawmakers also discussed separate measures aimed at refining regulations for medical marijuana access. Supporters of these initiatives, including the advocacy group Nebraskans for Medical Marijuana, gathered at the state capitol to protest efforts to overturn voter-approved measures. Despite extensive debate, no votes were cast on any cannabis-related legislation.

Armentano warned that the state’s attempt to override the election outcome is part of a broader trend seen in GOP-led states. He pointed to Ohio, where lawmakers recently pushed for new restrictions that rolled back voter-approved cannabis legalization, and South Dakota, where a similar attempt to repeal medical marijuana protections narrowly failed.

“In a democracy, different policy perspectives should be debated, and voters’ decisions should be respected,” Armentano stated. “But increasingly, opponents of cannabis reform are working to sideline voters entirely. Regardless of one’s stance on marijuana, these actions should be deeply concerning to anyone who values the democratic process.”

The cannabis industry, including enterprises like Green Thumb Industries Inc. (CSE: GTII) (OTCQX: GTBIF), is likely to be concerned by this growing trend in which lawmakers take steps to try and sideline what voters have decided during an election.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is powered by IBN

420 with CNW — Texas Senators Consider an Outright THC Ban

A Senate committee in Texas recently reviewed a proposed measure that seeks to prohibit all types of THC. SB 3, supported by Lieutenant Governor Dan Patrick, addresses concerns over illegal THC products being sold statewide.

Patrick argues that businesses are taking advantage of a legal loophole to sell potentially harmful substances. In 2019, Texas legalized the production and sale of hemp through the Hemp Farming Act, which allowed for cannabis plants with no more than 0.3% delta-9 THC.

Some business owners acknowledge the need for stricter regulations, such as age restrictions, but believe an outright ban is excessive. According to Jazmin Torres, proprietor of Zenblendz, a smoke shop that sells THC products, a large portion of her clientele consists of elderly folks and veterans who use the products for wellness purposes rather than for recreational purposes. She worries a comprehensive ban would kill the sector.

Hometown Hero, a marijuana wholesaler based in Austin, also voiced concerns. A company representative emphasized that their products offer a safer alternative to alcohol and warned that banning hemp-derived THC could drive sales underground, making regulation even more difficult. The company hopes to collaborate with lawmakers to ensure adult consumers and veterans can continue accessing these products responsibly.

A recent survey by the Hobby School of Public Affairs at the University of Houston examined public opinion on cannabis policies in Texas. While medical cannabis enjoys the most widespread support, there is also significant backing for more relaxed recreational use laws.

The study found that 69% of Texans favor decriminalizing cannabis possession, and 62% support legalizing recreational use and sales. Although opinions differ across political lines, a majority in both major parties back legalization, with 53% of Republicans and 71% of Democrats in favor.

Support for medical cannabis is even higher, with 79% of Texans believing it should be available with a prescription. Among Republicans, 75% endorse medical cannabis, while 86% of Democrats share this view.

Despite widespread backing for cannabis reform, more than 50% of Texans agree with the governor’s proposed ban on THC-infused consumables, which remain unregulated. The level of support varies across different groups: 61% of Republicans, 70% of Gen Z, 48% of Democrats, and 46% of baby boomers are in favor of restricting these products.

As lawmakers consider the economic and consumer impact of this proposal, the Senate State Affairs Committee will continue to assess the potential consequences of banning THC products in Texas.

The marijuana industry, including leading brands like Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) in other jurisdictions recognize that regulation is important, but lawmakers also need to find ways to regulate marijuana without stifling business.

About CNW420

To receive SMS alerts from CNW, text CANNABIS to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: https://www.CannabisNewsWire.com/Disclaimer

CannabisNewsWire
Denver, CO
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com